Survival and Prognostic Factors in C9orf72 Repeat Expansion Carriers: A Systematic Review and Meta-analysis.

Stella A Glasmacher, Charis Wong, Iona E Pearson, Suvankar Pal
Author Information
  1. Stella A Glasmacher: College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom.
  2. Charis Wong: Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
  3. Iona E Pearson: College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom.
  4. Suvankar Pal: Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.

Abstract

Importance: The c9orf72 repeat expansion (c9 or c9orf72RE) confers a survival disadvantage in amyotrophic lateral sclerosis (ALS); its effect on prognosis in frontotemporal dementia (FTD) remains uncertain. Data on prognostic factors in c9orf72RE disorders could inform patient care, genetic counseling, and trial design.
Objective: To examine prognostic factors in c9ALS, c9FTD, c9ALS-FTD, and atypical phenotypes.
Data Sources: The MEDLINE, Embase, Amed, ProQuest, PsychINFO, CINAHL, and LILACS databases were searched between January 2011 and January 2019. Keywords used were c9orf72 and chromosome 9 open reading frame 72. Reference lists, citations of eligible studies, and review articles were also searched by hand.
Study Selection: Studies reporting disease duration for patients with a confirmed c9orf72RE and a neurological and/or psychiatric disorder were included. A second author independently reviewed studies classified as irrelevant by the first author. Analysis began in January 2019.
Data Extraction and Synthesis: Data were extracted by 1 author; a further author independently extracted 10% of data. Data were synthesized in univariate and multivariable Cox regression and are displayed as hazard ratios (HR) and 95% confidence intervals.
Main Outcomes and Measures: Survival after symptom onset.
Results: Overall, 206 studies reporting on 1060 patients were included from 2878 publications identified (c9ALS: n = 455; c9FTD: n = 296; c9ALS-FTD: n = 198; atypical phenotypes: n = 111); 197 duplicate cases were excluded. The median (95% CI) survival (in years) differed significantly between patients with c9ALS (2.8 [2.67-3.00]), c9FTD (9.0 [8.09-9.91]), and c9ALS-FTD (3.0 [2.73-3.27]); survival in atypical phenotypes varied substantially. Older age at onset was associated with shorter survival in c9ALS (HR, 1.03; 95% CI, 1.02-1.04; P < .001), c9FTD (HR, 1.04; 95% CI, 1.02-1.06; P < .001), and c9ALS-FTD (HR, 1.02; 95% CI, 1.004-1.04; P = .016). Bulbar onset was associated with shorter survival in c9ALS (HR, 1.64; 95% CI, 1.27-2.08; P < .001). Age at onset and bulbar onset ALS remained significant in multivariable regression including variables indicating potential diagnostic ascertainment bias, selection bias, and reporting bias. Family history, sex, study continent, FTD subtype, or the presence of additional pathogenic sequence variants were not significantly associated with survival. Clinical phenotypes in patients with neuropathologically confirmed frontotemporal lobar degeneration-TDP-43, motor neuron disease-TDP-43 and frontotemporal lobar degeneration-motor neuron disease-TDP-43 were heterogenous and impacted on survival.
Conclusions and Relevance: Several factors associated with survival in c9orf72RE disorders were identified. The inherent limitations of our methodological approach must be considered; nonetheless, the reported prognostic factors were not significantly associated with the bias indicators examined.

References

  1. Mol Neurodegener. 2014 Sep 20;9:38 [PMID: 25239657]
  2. J Neurol Neurosurg Psychiatry. 2019 Jan;90(1):118-120 [PMID: 29661924]
  3. Acta Neuropathol. 2015 Sep;130(3):363-72 [PMID: 26022924]
  4. Lancet Neurol. 2012 Jan;11(1):54-65 [PMID: 22154785]
  5. Neurology. 1998 Dec;51(6):1546-54 [PMID: 9855500]
  6. Neuron. 2011 Oct 20;72(2):245-56 [PMID: 21944778]
  7. Acta Neuropathol. 2012 Jun;123(6):825-39 [PMID: 22426854]
  8. Arch Neurol. 2012 Dec;69(12):1583-90 [PMID: 22964832]
  9. Ann Neurol. 2015 Jan;77(1):100-13 [PMID: 25382069]
  10. Neuron. 2011 Oct 20;72(2):257-68 [PMID: 21944779]
  11. Neurobiol Aging. 2017 Mar;51:178.e11-178.e20 [PMID: 28089114]
  12. Neuroepidemiology. 2011;37(3-4):166-7 [PMID: 22056969]
  13. Neurobiol Aging. 2013 Dec;34(12):2890.e7-2890.e12 [PMID: 23870417]
  14. Acta Neuropathol. 2013 Dec;126(6):859-79 [PMID: 24096617]
  15. Neurobiol Aging. 2014 Dec;35(12):2882.e7-2882.e12 [PMID: 25123918]
  16. J Neurol Sci. 1994 Jul;124 Suppl:96-107 [PMID: 7807156]
  17. Eur J Neurol. 2017 Apr;24(4):e24 [PMID: 28322003]
  18. Neurobiol Aging. 2014 Oct;35(10):2421.e13-7 [PMID: 24866401]
  19. J Neurol Neurosurg Psychiatry. 2013 Feb;84(2):163-9 [PMID: 23117491]
  20. Acta Neuropathol. 2011 Dec;122(6):673-90 [PMID: 22083254]
  21. Acta Neuropathol. 2013 Sep;126(3):401-9 [PMID: 23818065]
  22. Neurology. 2016 Sep 6;87(10):1024-30 [PMID: 27488601]
  23. Neurology. 2011 May 31;76(22):1886-93 [PMID: 21624986]
  24. Ann Intern Med. 2009 Aug 18;151(4):W65-94 [PMID: 19622512]
  25. Neurology. 2017 Mar 7;88(10):991-999 [PMID: 28159885]
  26. Neurology. 2014 Jan 28;82(4):292-9 [PMID: 24363131]
  27. Acta Neuropathol. 2011 Dec;122(6):691-702 [PMID: 22101323]
  28. Rev Neurol (Paris). 2013 Oct;169(10):820-4 [PMID: 24012408]
  29. Hum Mutat. 2013 Jan;34(1):79-82 [PMID: 22936364]
  30. Brain. 2012 Mar;135(Pt 3):751-64 [PMID: 22366792]
  31. Clin Genet. 2017 Sep;92(3):259-266 [PMID: 28105640]
  32. Lancet Neurol. 2012 Mar;11(3):232-40 [PMID: 22305801]
  33. Ann Neurol. 2017 Jul;82(1):139-146 [PMID: 28628244]
  34. Ophthalmic Physiol Opt. 2014 Sep;34(5):502-8 [PMID: 24697967]
  35. Acta Neuropathol. 2019 Jan;137(1):27-46 [PMID: 30511086]
  36. Lancet Neurol. 2013 Oct;12(10):978-88 [PMID: 24011653]
  37. Front Neurosci. 2019 May 17;13:485 [PMID: 31156370]
  38. Lancet Neurol. 2010 Aug;9(8):793-806 [PMID: 20650401]
  39. J Neurol. 2016 Mar;263(3):558-74 [PMID: 26810719]
  40. Mol Neurodegener. 2013 Apr 08;8:12 [PMID: 23566336]
  41. Neurobiol Aging. 2012 Oct;33(10):2528.e7-14 [PMID: 22766072]
  42. Bipolar Disord. 2013 May;15(3):326-32 [PMID: 23551834]
  43. JAMA Neurol. 2014 Jun;71(6):771-4 [PMID: 24733620]
  44. J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):281 [PMID: 27663272]
  45. Hum Mol Genet. 2014 Feb 1;23(3):749-54 [PMID: 24057670]
  46. Arch Neurol. 2009 Nov;66(11):1359-64 [PMID: 19901167]
  47. J Alzheimers Dis. 2015;45(1):319 [PMID: 25737153]
  48. Dement Geriatr Cogn Dis Extra. 2013 Aug 20;3(1):251-62 [PMID: 24052799]
  49. Alzheimers Res Ther. 2012 Oct 03;4(5):38 [PMID: 23034079]
  50. PLoS One. 2015 May 27;10(5):e0127376 [PMID: 26016851]
  51. Ann Clin Transl Neurol. 2016 Jul 01;3(8):623-36 [PMID: 27606344]
  52. Hum Mol Genet. 2015 Jun 1;24(11):3133-42 [PMID: 25712133]
  53. Brain. 2012 Mar;135(Pt 3):784-93 [PMID: 22366794]
  54. Brain. 2012 Mar;135(Pt 3):765-83 [PMID: 22366793]
  55. J Med Genet. 2013 Nov;50(11):776-83 [PMID: 23881933]
  56. Neurobiol Aging. 2014 May;35(5):1214.e7-1214.e10 [PMID: 24387986]
  57. Dement Geriatr Cogn Disord. 2016;41(1-2):109-22 [PMID: 26854827]
  58. J Neuropathol Exp Neurol. 2018 Aug 1;77(8):703-709 [PMID: 29889265]
  59. Curr Opin Genet Dev. 2017 Jun;44:117-124 [PMID: 28319737]
  60. Amyotroph Lateral Scler. 2012 Oct;13(6):493-501 [PMID: 22424127]
  61. Neurobiol Aging. 2012 Aug;33(8):1848.e15-20 [PMID: 22418734]
  62. JAMA Neurol. 2014 Mar;71(3):331-9 [PMID: 24445580]
  63. Neurology. 2012 Sep 4;79(10):1002-11 [PMID: 22875087]
  64. Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):310-23 [PMID: 19922118]

MeSH Term

Aged
Amyotrophic Lateral Sclerosis
C9orf72 Protein
DNA Repeat Expansion
Female
Frontotemporal Dementia
Humans
Male
Middle Aged
Prognosis
Risk Factors

Chemicals

C9orf72 Protein
C9orf72 protein, human

Word Cloud

Created with Highcharts 10.0.01survival95%HRonsetCIassociatedc9orf72REfactorsc9ALSpatientsauthorbiasfrontotemporalDataprognosticc9FTDc9ALS-FTDatypicalphenotypesJanuarystudiesreportingsignificantly04P <001c9orf72ALSFTDdisordersDatasearched20199confirmedincludedindependentlyextractedmultivariableregressionSurvivalidentified[20shorter02-1lobarneurondisease-TDP-43Importance:repeatexpansionc9confersdisadvantageamyotrophiclateralsclerosiseffectprognosisdementiaremainsuncertaininformpatientcaregeneticcounselingtrialdesignObjective:examineSources:MEDLINEEmbaseAmedProQuestPsychINFOCINAHLLILACSdatabases2011Keywordsusedchromosomeopenreadingframe72ReferencelistscitationseligiblereviewarticlesalsohandStudySelection:Studiesdiseasedurationneurologicaland/orpsychiatricdisordersecondreviewedclassifiedirrelevantfirstAnalysisbeganExtractionSynthesis:10%datasynthesizedunivariateCoxdisplayedhazardratiosconfidenceintervalsMainOutcomesMeasures:symptomResults:Overall20610602878publicationsc9ALS:n = 455c9FTD:n = 296c9ALS-FTD:n = 198phenotypes:n = 111197duplicatecasesexcludedmedianyearsdiffered2867-300][809-991]373-327]variedsubstantiallyOlderage030602004-1P = 016Bulbar6427-208AgebulbarremainedsignificantincludingvariablesindicatingpotentialdiagnosticascertainmentselectionFamilyhistorysexstudycontinentsubtypepresenceadditionalpathogenicsequencevariantsClinicalneuropathologicallydegeneration-TDP-43motordegeneration-motorheterogenousimpactedConclusionsRelevance:SeveralinherentlimitationsmethodologicalapproachmustconsiderednonethelessreportedindicatorsexaminedPrognosticFactorsC9orf72RepeatExpansionCarriers:SystematicReviewMeta-analysis

Similar Articles

Cited By